Roa, Juan C. http://orcid.org/0000-0001-8313-8774
GarcĂa, Patricia
Kapoor, Vinay K.
Maithel, Shishir K.
Javle, Milind
Koshiol, Jill
Article History
Accepted: 20 September 2022
First Online: 27 October 2022
Change Date: 18 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41572-022-00408-z
Competing interests
: M.J. receives research funding (to Institution) from Merck, EMD Serono, Novartis, Eli Lilly, AstraZeneca, Genentech, Transthera, Meclun, BMS, Incyte, QED, Taiho, Servier, Oncosil, Basilea, Nucana; and to self or as advisory board/Data and Safety Monitoring Board member from Incyte, Zymeworks, Mundi Pharma, Nucana, MORE health and Origimed. Peer grant funding is provided from Department of Defense and NIH. S.K.M. receives research funding (to Institution) from BMS, QED/HELSINN, Natera. The other authors (J.C.R., P.G., J.K. and V.K.K.) declare no competing interests.